Learn to track real recovery in major depressive disorder by monitoring mood, energy, cognition, and quality of life for ...

CLARITY (Clinical Assessment of Response in the Treatment of Depression with Daytime Sleepiness Using Solriamfetol) is a Phase 3, double-blind, placebo-controlled, multicenter randomized withdrawal ...

A team of leading clinical research scientists from the Departments of Psychiatry and Dermatology at the Icahn School of ...

Major depressive disorder is linked to Th2 immune dysregulation similar to atopic dermatitis. Could dupilumab offer a new ...

Dimethyltryptamine’s short duration of psychedelic effects makes it a potentially practical alternative to other longer-acting psychedelic therapies such as psilocybin.

DMT therapy significantly reduced major depressive disorder symptoms in a phase IIa trial. Learn more about this rapid-acting ...

Wearable trackers could even detect the probability of a relapse weeks or months before it occurs. Up to around 60% of people with MDD will experience at least one relapse episode in their lifetime.

Findings provide rationale for targeted strategy in psychiatry that may lead to new personalized treatments for major depressive disorder and other conditions ...

Major depressive disorder (MDD) can cause more than depression. It can lead to complications that affect your health and change how you think and behave. When you’re depressed, it’s no surprise you ...

Smartwatches may soon warn of depression relapse weeks in advance by detecting disrupted sleep and daily routines, offering a passive way to monitor mental health.